GlassScriptPhysician profile
Sarah Balla
NPI 1427653765
$11,336.09
in general payments reported to CMS, 2019-2025
44 companies · $2,102 in 2025
The $2,102 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,885 · 2022: $2,363 · 2023: $2,484 · 2024: $2,501 · 2025: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,087.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.02 | 2021-2025 | |
| Lilly USA, LLC | $1,238.16 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,180.00 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,080.50 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $708.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $672.34 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $631.27 | 2021-2025 | |
| Amgen INC. | $480.51 | 2021-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.76 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $419.17 | 2021-2025 | Trintellix |
| Exact Sciences Corporation | $274.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $271.41 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.59 | 2021-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $233.45 | 2021-2025 | Verquvo, Gardasil 9, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $229.70 | 2021-2025 | Eliquis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Balla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.